US approval for GSK/Valeant/Meda anti-epileptic, Potiga, with conditions
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals, Meda and GlaxoSmithKline have claimed a first after finally receiving US approval for the anti-epileptic, Potiga (ezogabine), for use as an adjunctive treatment of partial-onset seizures in patients aged 18 years and older.